CO2 Transoral Laser Microsurgery for Early Glottic Carcinoma with Anterior Commissure Involvement.
Yetao Yin,Qian Cai,Yiqing Zheng,Xiaoming Huang,Jieren Peng,Faya Liang,Jinshan Yang,Wenjun Chen,Yuejia Su,Zhong Guan
DOI: https://doi.org/10.1016/j.anl.2022.09.006
IF: 2.119
2023-01-01
Auris Nasus Larynx
Abstract:Objective: Anterior commissure (AC) involvement is an unfavorable factor for transoral laser microsurgery (TLM) treatment of early glottic carcinoma (EGC). This study aimed to evaluate the therapeutic efficacy of TLM treatment for EGC with AC involvement.Methods: From 2008 to 2017, 177 patients with T1-T2 EGC with AC involvement were retrospectively included and divided into the TLM group (n = 115) receiving CO 2 laser TLM and the control group undergoing open surgery (n = 62). The survival outcomes, postoperative complications, laryngeal preservation rate, recurrence and the phonological results were compared between groups.Result: The TLM group had significantly reduced hospital stay, hospitalization costs, and intraoperative blood loss as compared with the control group. The tracheotomy rate was significantly higher in the control group (96.8% vs. 0%). The 5-year overall survival (OS) was 89.6% and 85.5% in the TLM group and control group, respectively. Log-rank test showed no difference in survival rate between the two groups. There was no significant difference in laryngeal preservation rate and overall recurrence rate between groups. In postoperative vocal function evaluation, there were significant differences in the overall grade (G), the roughness (R), the breathiness (B), Voice Handicap Index-10 (VHI-10), Jitter, Shimmer, noise/harmonic ratio (NHR), maximum phonation time (MPT), phonation threshold pressure (PTP) between the two groups.Conclusion: For EGC with AC involvement, TLM has similar survival outcomes with the open surgery, but has better postoperative voice outcomes. Meanwhile, TLM can effectively reduce intraoperative blood loss, hospitalization time, hospitalization costs and postoperative complications. (c) 2022 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights reserved.